Abstract:To evaluate if breast-conserving therapy achieved superior efficacy to modified radical mastectomy in patients with T1-2N1M0 breast cancer. 2776 women with T1-2N1M0 breast cancer treated from 1999 to 2013 were retrospectively reviewed. All had received lumpectomy or mastectomy and axillary lymph node dissection without neoadjuvant chemotherapy. The median age was 49 years. 2484 patients underwent modified radical mastectomy (MRM), 580 (23.3%) of them received postoperative RT (MRM + RT). 292 patients received breast-conserving surgery (BCT), all of them received postoperative RT. For the whole group, 92.7% of received postoperative chemotherapy and 4.9% received trastuzumab targeted therapy. Of the 2148 patients with ER and/or PR positive, 87.7% received hormonal therapy. Survival and recurrence rates were calculated by using the Kaplan-Meier method and compared by log-rank test. Multivariable analysis was estimated by using the Cox proportional hazards model. At a median follow-up of 59 months (range, 1-257 months), the 5-year overall survival (OS) of the BCT and MRM groups was 97.9% and 92.9% (p= 0.014), and the 5-year locoregional recurrence (LRR) was 2.3% vs 6.1% (p= 0.022). Of MRM group, the 5-year OS was 92.7% in MRM alone and 93.5% in MRM + RT (p = 0.037), and the 5-year LRR was 6.3% and 5.2%, respectively (p = 0.188). Furthermore, the 5-year OS of BCT group was significantly higher than that of MRM alone (p = 0.007), however there was no significant difference in OS between BCT and MRM + RT (P = 0.160). The 5-year LRR of BCT group was significantly lower than that of MRM alone (p = 0.016), but had no significant difference with MRM + RT (p = 0.094). Univariate analysis showed that age ≤ 60 years, tumor grade I-II, T1, luminal subtype, no lymph-vascular invasion, BCT, RT, chemotherapy and hormonal therapy were favorable factors of OS (P <0.05). Age > 60 years, tumor grade I-II, T1, one axillary lymph node metastasis, luminal subtype, BCT, RT and hormonal therapy were favorable factors of LRR (P <0.05). Multivariate analysis showed that age (p = 0.009), T stage (p <0.001), molecular subtype (p = 0.009) and chemotherapy (p <0.001) were independent prognostic factors for OS. RT (p = 0.054) and hormonal therapy (p = 0.063) had a trend to improve OS. Age (p = 0.034), T stage (p = 0.002), molecular subtype (p <0.001), RT (P = 0.001) and the number of positive axillary lymph node (P <0.001) were independent prognostic factors for LRR. The type of breast surgery had no significant effect on OS (p = 0.388) and LRR (p = 0.836). The type of breast surgery had no significant effect on the prognosis of patients with T1-2N1M0 breast cancer. Postoperative radiotherapy significantly reduces the risk of locoregional recurrence and might improve overall survival, suggesting that it may be required for majority of patients with mastectomy.

ER, PR and Her-2 in the prediction of locoregional recurrence in node positive breast cancer treated with mastectomy

[Prognostic Value of Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor-2 in Node Positive Breast Cancer Patients Treated by Mastectomy].

EFFECT OF ADJUVANT ENDOCRINE THERAPY ON ESTROGEN RECEPTOR-NEGATIVE, PROGESTERONE RECEPTOR-POSITIVE AND HER2 NEGATIVE BREAST CANCER PATIENTS

Radiotherapy following modified radical mastectomy significantly improves locoregional control in patients with Rec-/HER-2+ locally advanced breast cancer

Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy.

Role of radiotherapy and prognostic factors in breast cancer patients at high-risk of recurrence trea-ted with modified radical mastectomy and chemotherapy

Locoregional Recurrence Risk in Breast Cancer Patients with Estrogen Receptor Positive Tumors and Residual Nodal Disease following Neoadjuvant Chemotherapy and Mastectomy without Radiation Therapy

Establishment of a risk scoring system for predicting locoregional recurrence in T1 to T2 node-negative breast cancer patients treated with mastectomy: Implications for postoperative radiotherapy.

The Role of Postmastectomy Radiotherapy in Breast Cancer Patients with T1-T2 and One to Three Positive Axillary Nodes

The Role of Postmastectomy Radiation Therapy in Locally Advanced Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Mastectomy

Radiotherapy for and Prognosis of Breast Cancer Patients with Local-Regional Recurrence after Mastectomy

Biological subtype predicts locoregional recurrence after postmastectomy radiotherapy in Chinese breast cancer patients.

Risk Stratification Model for Prediction of Locoregional Recurrence in Patients with Pathologic T1-2N0 Breast Cancer after Mastectomy

Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy?

Radiotherapy Can Improve The Disease-Free Survival Rate In Triple-Negative Breast Cancer Patients With T1-T2 Disease And One To Three Positive Lymph Nodes After Mastectomy

A Recurrence Risk Score Model Evaluating Effects of Postmastectomy Radiotherapy in Breast Cancer Patients with Pathologically Negative Lymph Nodes after Neoadjuvant Chemotherapy: A Multicenter, Retrospective Study

Radiotherapy May Play an Important Role in Improving the Efficacy of Breast-Conserving Therapy Compared with Mastectomy in Patients with T1-2N1M0 Breast Cancer

Impact of Clinical-pathological Factors on Locoregional Recurrence in Mastectomy Patients with T1-2N1 Breast Cancer: Can We Omit Adjuvant Radiotherapy?

Outcomes in Patients with pT3N0M0 Breast Cancer with and without Postmastectomy Radiotherapy

Risk Factors of Locoregional Relapse in Locally Advanced Breast Cancer Treated with Neoadjuvant Chemotherapy Following Mastectomy and Radiotherapy

Analysis In Early Stage Triple-Negative Breast Cancer Treated With Mastectomy Without Adjuvant Radiotherapy: Patterns Of Failure And Prognostic Factors